These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 24576511)

  • 21. How to Prescribe Drugs With an Identified Proarrhythmic Liability.
    Thind M; Rodriguez I; Kosari S; Turner JR
    J Clin Pharmacol; 2020 Mar; 60(3):284-294. PubMed ID: 31743455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes.
    Bass AS; Darpo B; Breidenbach A; Bruse K; Feldman HS; Garnes D; Hammond T; Haverkamp W; January C; Koerner J; Lawrence C; Leishman D; Roden D; Valentin JP; Vos MA; Zhou YY; Karluss T; Sager P
    Br J Pharmacol; 2008 Aug; 154(7):1491-501. PubMed ID: 18663380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays.
    Trepakova ES; Koerner J; Pettit SD; Valentin JP;
    J Pharmacol Toxicol Methods; 2009; 60(1):45-50. PubMed ID: 19439186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-induced Proarrhythmia and Torsade de Pointes: A Primer for Students and Practitioners of Medicine and Pharmacy.
    Turner JR; Rodriguez I; Mantovani E; Gintant G; Kowey PR; Klotzbaugh RJ; Prasad K; Sager PT; Stockbridge N; Strnadova C;
    J Clin Pharmacol; 2018 Aug; 58(8):997-1012. PubMed ID: 29672845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prospective IQ-CSRC trial: A prototype early clinical proarrhythmia assessment investigation for replacing the ICH E14 thorough QTc (TQT) study.
    Cavero I; Holzgrefe H; Clements M
    J Pharmacol Toxicol Methods; 2016; 80():1-8. PubMed ID: 26903171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Moving towards better predictors of drug-induced Torsade de Pointes. 2-3 November 2005, Crystal City, Virginia, USA.
    Cavero I; Crumb W
    Expert Opin Drug Saf; 2006 Mar; 5(2):335-40. PubMed ID: 16503753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early drug development: assessment of proarrhythmic risk and cardiovascular safety.
    Lester RM; Olbertz J
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1611-1618. PubMed ID: 27718759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiologist's point of view: Novel ECG biomarkers and in silico models for proarrhythmic risk prediction: Are we ready?
    Mason JW
    J Electrocardiol; 2017; 50(6):825-827. PubMed ID: 28919218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig.
    Guns PJ; Johnson DM; Weltens E; Lissens J
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):125-34. PubMed ID: 22516473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs.
    Vicente J; Stockbridge N; Strauss DG
    J Electrocardiol; 2016; 49(6):837-842. PubMed ID: 27524478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
    Shantsila E; Watson T; Lip GY
    Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
    Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
    Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reducing QT liability and proarrhythmic risk in drug discovery and development.
    Valentin JP
    Br J Pharmacol; 2010 Jan; 159(1):5-11. PubMed ID: 20141515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.
    Huang H; Pugsley MK; Fermini B; Curtis MJ; Koerner J; Accardi M; Authier S
    J Pharmacol Toxicol Methods; 2017 Sep; 87():11-23. PubMed ID: 28408211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of Normalized TdP Score System in Drug Proarrhythmic Potential Assessment: A Blinded in vitro Study of CiPA Drugs.
    Liu T; Liu J; Lu HR; Li H; Gallacher DJ; Chaudhary K; Wang Y; Yan GX
    Clin Pharmacol Ther; 2021 Jun; 109(6):1606-1617. PubMed ID: 33283267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs.
    Koshman YE; Wilsey AS; Bird BM; Endemann AL; Sadilek S; Treadway J; Martin RL; Polakowski JS; Gintant GA; Mittelstadt SW
    J Pharmacol Toxicol Methods; 2020; 103():106871. PubMed ID: 32360993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. QT interval and drug therapy.
    Drug Ther Bull; 2016 Mar; 54(3):33-6. PubMed ID: 26966121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug induced shortening of the QT/QTc interval: an emerging safety issue warranting further modelling and evaluation in drug research and development?
    Holbrook M; Malik M; Shah RR; Valentin JP
    J Pharmacol Toxicol Methods; 2009; 59(1):21-8. PubMed ID: 18834945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-induced proarrhythmia: Discussion and considerations for clinical practice.
    Klotzbaugh RJ; Martin A; Turner JR
    J Am Assoc Nurse Pract; 2020 Feb; 32(2):128-135. PubMed ID: 32015278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.